GlassScriptPhysician profile
Alan Cartmell
NPI 1316933021
$2,275.15
in general payments reported to CMS, 2019-2025
38 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $59.82 · 2021: $54.07 · 2022: $205 · 2023: $731 · 2024: $855 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $479.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $341.85 | 2020-2024 | Ojjaara, Zejula, Jemperli |
| Exelixis INC. | $164.53 | 2023-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $164.32 | 2021-2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $133.64 | 2019-2024 | Opdualag, Opdivo |
| Celgene Corporation | $106.65 | 2021-2023 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $74.26 | 2022-2023 | Padcev |
| Daiichi Sankyo INC. | $72.40 | 2023-2024 | Injectafer, Vanflyta |
| Amgen INC. | $67.46 | 2019-2023 | Xgeva, Nplate |
| Octapharma USA, INC. | $57.34 | 2019 | |
| Janssen Biotech, INC. | $55.97 | 2019 | |
| Beigene USA, INC. | $32.74 | 2023 | Brukinsa |
| Genzyme Corporation | $31.97 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $30.31 | 2023 | Sancuso |
| Takeda Pharmaceuticals U.S.A., INC. | $29.53 | 2023 | Alunbrig |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $27.45 | 2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $24.38 | 2024 | Libtayo |
| Rigel Pharmaceuticals, INC. | $24.03 | 2022 | |
| Immunogen, INC. | $23.09 | 2023 | Elahere |
| Astrazeneca Pharmaceuticals LP | $22.81 | 2024 | Tagrisso |
| Agios Pharmaceuticals, INC. | $22.35 | 2024 | |
| Emd Serono, INC. | $20.49 | 2023 | Tepmetko |
| Mirati Therapeutics, INC. | $20.44 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $20.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.98 | 2020 | |
| Deciphera Pharmaceuticals INC. | $19.81 | 2024 | Qinlock |
| Seagen INC. | $19.67 | 2022 | |
| Abbvie INC. | $19.59 | 2024 | |
| Gilead Sciences, INC. | $19.46 | 2023 | |
| Kyowa Kirin, INC. | $19.19 | 2022 | |
| Incyte Corporation | $17.23 | 2025 | Niktimvo, Jakafi |
| Sobi, INC | $16.70 | 2023 | |
| Pfizer INC. | $16.69 | 2024 | |
| Genentech USA, INC. | $15.66 | 2022 | |
| Lilly USA, LLC | $15.01 | 2024 | Verzenio |
| Alexion Pharmaceuticals, INC. | $14.65 | 2024 | Ultomiris |
| Eisai INC. | $14.19 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cartmell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.